GFAP and in situ carcinoma: HLA-DRB1*15:01-risk, but not GFAP or anti-EBNA1 IgG, improved predictive value.<h4>Conclusion</h4>Our study found that serum NfL outperformed GFAP in predicting early MS diagnoses after CIS.